Changing the prognosis of pulmonary arterial hypertension: Impact of medical therapy

Research output: Contribution to journalReview articlepeer-review

9 Scopus citations


Pulmonary arterial hypertension (PAH) is a progressive arteriopathy of the pulmonary circulation that can affect a wide group of patients. Presentation and natural history of PAH are intimately linked to progressive right ventricular failure. Historically, survival in PAH has been poor, especially for patients with PAH associated with progressive systemic sclerosis and human immunodeficiency virus. Oral, subcutaneous, and intravenous therapies that have emerged during the last decade can improve symptoms and hemodynamics. This review explores the impact of these therapies on prognosis in PAH, which ultimately rests on the ability to reverse the pulmonary arteriopathy and preserve right ventricular function.

Original languageEnglish
Pages (from-to)409-416
Number of pages8
JournalSeminars in Respiratory and Critical Care Medicine
Issue number4
StatePublished - Aug 1 2005


  • Epoprostenol
  • Prognosis
  • Pulmonary arterial hypertension


Dive into the research topics of 'Changing the prognosis of pulmonary arterial hypertension: Impact of medical therapy'. Together they form a unique fingerprint.

Cite this